In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily treated Multiple myeloma (MM) have to be explored, without "a priori" exclusion of ancient drugs, even after failure of the ultimate pharmacological options.
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide / Cerchione, Claudio; Nappi, Davide; DI PERNA, Maria; Zacheo, Irene; Migliaccio, Ilaria; Salvatore, Dalila; Picardi, Marco; Pane, Fabrizio; Catalano, Lucio. - In: CLINICAL CASE REPORTS. - ISSN 2050-0904. - 5:4(2017), pp. 505-507. [10.1002/ccr3.773]
A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
CERCHIONE, CLAUDIO;NAPPI, DAVIDE;DI PERNA, MARIA;MIGLIACCIO, ILARIA;SALVATORE, DALILA;PICARDI, MARCO;PANE, FABRIZIO;CATALANO, LUCIO
2017
Abstract
In this report, we would like to highlight the efficacy of bendamustine in a heavily pretreated patient, also refractory to pomalidomide. It is conceivable that different therapy combinations in heavily treated Multiple myeloma (MM) have to be explored, without "a priori" exclusion of ancient drugs, even after failure of the ultimate pharmacological options.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.